Immunitas Therapeutics Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting On April 17, 2026, Immunitas Therapeutics announced it will present clinical data from its Phase 1/2a trial of IMT-009 at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, held April 17–22, 2026. The presentation, scheduled for Monday, April 20, 2026, from 9:00 a.m. To 12:00 p.m. PT in Poster Section 50, highlights findings from a first-in-human dose escalation and biomarker cohort expansion study of IMT-009 in advanced cancer, along with a Phase 1b combination trial with fruquintinib in microsatellite stable colorectal cancer (MSS CRC). IMT-009 is a fully human, Fc-attenuated IgG1 monoclonal antibody designed to bind CD161 and block its interaction with CLEC2D. Preclinical research indicates that inhibiting the CD161/CLEC2D pathway enhances anti-tumor activity. The ongoing Phase 1/2a clinical trial evaluates IMT-009 as both a monotherapy and in combination regimens for solid tumors and hematologic malignancies, with objectives including safety, tolerability, pharmacodynamic biomarker assessment, preliminary efficacy, and identification of the recommended Phase 2 dose. The company’s lead program, IMT-009, is currently under clinical investigation for patients with refractory tumors across multiple indications, including MSS colorectal cancer, head and neck cancer, and non-small cell lung cancer. Immunitas Therapeutics, founded by a team of cancer research and therapeutic antibody experts from institutions such as Dana Farber Cancer Institute, Massachusetts General Cancer Center, the Broad Institute, and MIT, is advancing IMT-009 through clinical evaluation as part of its broader pipeline of immuno-oncology and autoimmune disease therapeutics. The April 17, 2026 announcement follows earlier disclosures, including the January 4, 2023 report of the first patient dosed in the Phase 1/2a study of IMT-009 and the July 30, 2025 presentation of preclinical data on IMT-380, a separate anti-CD161 antibody targeting pathogenic T cells in autoimmune diseases. Immunitas Therapeutics continues to develop novel, antibody-based therapies grounded in specialized knowledge of the CD161-CLEC2D pathway, with a focus on translating biological insights into clinical advancements for patients with cancer and autoimmune conditions.
58